N-Methyl-DOI, also known as 2,5-dimethoxy-4-iodo-N-methylamphetamine (2,5-IDNA), is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families related to the serotonergic psychedelic DOI. It is a potent agonist of the serotonin 5-HT2A receptor similarly to DOI. However, N-methyl-DOI was about 3.8-fold less potent than DOI as a serotonin 5-HT2A receptor agonist in terms of EC50Tooltip half-maximal effective concentration and showed reduced maximal efficacy compared to DOI (EmaxTooltip maximal efficacy = 64% vs. 83%). On the other hand, it showed similar efficacy in activating the serotonin 5-HT2A receptor to the psychedelic 2C-I (Emax = 68%). N-Methyl-DOI was first described in the scientific literature, as a potential radiopharmaceutical for medical imaging, by Alexander Shulgin and colleagues by 1984. It is a controlled substance in Canada under phenethylamine blanket-ban language.
See also DOx (psychedelics) IDNNA (N,N-dimethyl-DOI) Methyl-DOB (N-methyl-DOB) N-Methyl-2C-I N-Methyl-2C-B Beatrice (N-methyl-DOM) N-Methyl-DOET
References
External links N-Methyl-DOI - Isomer Design


